Mr. Guiffre continued, "The rate of disease progression in patients appears to have slowed down recently in our blinded trial of CRLX101 in combination with Avastin® (bevacizumab) in relapsed renal cell carcinoma (RCC); accordingly, we now expect top-line results in the third quarter 2016."
What i interpret here is the drug work, the progression free survival prolonged so they need longer duration for the final data collection.
The survival rate for sAML is about 6 months, so does it means for the trial to meet the primary endpoint is to have survival rate about 36.5% more than 6 months = 8.2 months?
Correct me if I am wrong.
I believe most investor sell it because it has no binary event until Q4 2016. And most of the investor do take profit after a huge ride in 2015. They will come back when the investment environment getting better.
Any thing that can make share price spike?
That is the purpose i requesting here. Last time when I invest in AVNR, there are ppl that post the weekly prescription in MB (source from Symphony and IMS health)
If you happen to be one of the big fish , pls share the info here!
Anyone can track the weekly prescription for ILUVIEN?
Thanks in advance.
Will POZN still receive 20mlm from SANOFI if PA approved?
Two Stage Study Of Single Dose PEGPH20 And Cetuximab In Patients With Pancreatic Adenocarcinoma Prior To Surgical Resection
Memorial Sloan-Kettering Cancer Center
Cold Spring Harbor Laboratory
worth to watch?
25 mlm milestone payment already = 20% of 125m Market cap
An FDA approval = 0% value added to the company ? Isn't that ridiculous?